EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial

Hari T Vigneswaran iD, Martin Eklund iD, Andrea Discacciati, Tobias Nordström, Rebecca A Hubbard iD, Nathan Perlis, Michael R Abern, Daniel M Moreira, Scott Eggener iD, Paul Yonover, Alexander K Chow, Kara Watts und 10 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00152 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Hari T Vigneswaran und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort. METHODS An observational prospective multicentered (17 sites) clinical trial (2019-2023), supplemented by prospectively recruited participants (2008-2020) in a urology clinic setting included men with suspicion of PCa and underwent prostate biopsy. Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. The primary endpoint was detection of International Society of Urological Pathology (ISUP) Grade ≥2 cancer (clinically significant PCa, csPC). The two primary aims were to (1) demonstrate noninferior sensitivity (0.8 lower bound 95% CI noninferiority margin) in detecting csPC using Stockholm3 compared with PSA (relative sensitivity) and (2) demonstrate superior specificity by reducing biopsies with benign results or low-grade cancers (relative specificity). RESULTS A total of 2,129 biopsied participants were included: Asian (16%, 350), Black or African American (Black; 24%, 505), Hispanic or Latino and White (Hispanic; 14%, 305), and non-Hispanic or non-Latino and White (White; 46%, 969). Overall, Stockholm3 showed noninferior sensitivity compared with PSA ≥4 ng/mL (relative sensitivity: 0.95 [95% CI, 0.92 to 0.99]) and nearly three times higher specificity (relative specificity: 2.91 [95% CI, 2.63 to 3.22]). Results were consistent across racial and ethnic subgroups: noninferior sensitivity (0.91-0.98) and superior specificity (2.51-4.70). Compared with PSA, Stockholm3 could reduce benign and ISUP 1 biopsies by 45% overall and between 42% and 52% across racial and ethnic subgroups. CONCLUSION In a substantially diverse population, Stockholm3 significantly reduces unnecessary prostate biopsies while maintaining a similar sensitivity to PSA in detecting csPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleProspective StudiesAgedMiddle AgedProstate-Specific AntigenBiomarkers, TumorBiopsy

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Urology, University of Illinois at Chicago, Chicago, IL.
  • Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Department of Surgery, University of Toronto, University Health Network, Toronto, Canada.
  • Department of Surgery, Duke University School of Medicine, Durham, NC.
  • Department of Surgery, University of Chicago, Chicago, IL.

ORCID-Profile: Hari T Vigneswaran, Martin Eklund, Rebecca A Hubbard, Scott Eggener, Andre L Abreu, Geoffrey A Sonn, Thorgerdur Palsdottir, Anna Plym, Henrik Grönberg, Adam B Murphy

Förderung

  • NCI NIH HHS

Zitieren

APA

Vigneswaran, H. T., Eklund, M., Discacciati, A., Nordström, T., Hubbard, R. A., Perlis, N., Abern, M. R., Moreira, D. M., Eggener, S., Yonover, P., Chow, A. K., Watts, K., Liss, M. A., Thoreson, G. R., Abreu, A. L., Sonn, G. A., Palsdottir, T., Plym, A., Wiklund, F., …, & SEPTA STHLM3 Study Group (2024). Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00152

Vancouver

Vigneswaran HT, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, et al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00152

BibTeX
@article{Vigneswaran2024,
  author = {Vigneswaran, Hari T and Eklund, Martin and Discacciati, Andrea and Nordström, Tobias and Hubbard, Rebecca A and Perlis, Nathan and Abern, Michael R and Moreira, Daniel M and Eggener, Scott and Yonover, Paul and Chow, Alexander K and Watts, Kara and Liss, Michael A and Thoreson, Gregory R and Abreu, Andre L and Sonn, Geoffrey A and Palsdottir, Thorgerdur and Plym, Anna and Wiklund, Fredrik and Grönberg, Henrik and Murphy, Adam B and SEPTA STHLM3 Study Group, SEPTA STHLM3 Study Group},
  title = {Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00152}
}
Kostenlos starten →